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Abstract
Background: Burn survivors develop long-term cognitive impairment with increased inflammation and apoptosis
in the brain. Gelsolin, an actin-binding protein with capping and severing activities, plays a crucial role in the septic
response. We investigated if gelsolin infusion could attenuate neural damage in burned mice.
Methods: Mice with 15% total body surface area burns were injected intravenously with bovine serum albumin as
placebo (2 mg/kg), or with low (2 mg/kg) or high doses (20 mg/kg) of gelsolin. Samples were harvested at 8, 24,
48 and 72 hours postburn. The immune function of splenic T cells was analyzed. Cerebral pathology was examined
by hematoxylin/eosin staining, while activated glial cells and infiltrating leukocytes were detected by
immunohistochemistry. Cerebral cytokine mRNAs were further assessed by quantitative real-time PCR, while
apoptosis was evaluated by caspase-3. Neural damage was determined using enzyme-linked immunosorbent assay
of neuron-specific enolase (NSE) and soluble protein-100 (S-100). Finally, cerebral phospho-ERK expression was
measured by western blot.
Results: Gelsolin significantly improved the outcomes of mice following major burns in a dose-dependent manner.
The survival rate was improved by high dose gelsolin treatment compared with the placebo group (56.67% vs.
30%). Although there was no significant improvement in outcome in mice receiving low dose gelsolin (30%),
survival time was prolonged against the placebo control (43.1 ± 4.5 h vs. 35.5 ± 5.0 h; P < 0.05). Burn-induced T
cell suppression was greatly alleviated by high dose gelsolin treatment. Concurrently, cerebral abnormalities were
greatly ameliorated as shown by reduced NSE and S-100 content of brain, decreased cytokine mRNA expressions,
suppressed microglial activation, and enhanced infiltration of CD11b+ and CD45+ cells into the brain. Furthermore,
the elevated caspase-3 activity seen following burn injury was remarkably reduced by high dose gelsolin treatment
along with down-regulation of phospho-ERK expression.
Conclusion: Exogenous gelsolin infusion improves survival of mice following major burn injury by partially
attenuating inflammation and apoptosis in brain, and by enhancing peripheral T lymphocyte function as well.
These data suggest a novel and effective strategy to combat excessive neuroinflammation and to preserve
cognition in the setting of major burns.
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Brain is one of the remote organs subjected to injurious
effects of severe burns [1]. Survivors suffering from
extensive burn injury present long-term cognitive
impairment, including depression, anxiety, post-trau-
matic stress disorder [2,3], and alteration in painful sen-
sation as well as sensory sensitivity in later life [4]. In
animal studies, magnetic resonance imaging has identi-
fied marked changes in the brain up to 3 days postburn
(pb), most notably swelling and lesions [5], changes in
cerebral blood flow [6], dysregulation of glucose meta-
bolism [7], and disruption of the blood-brain barrier
(BBB) [8,9].
Neuroinflammation is a frequent consequence of sep-
sis and septic shock [10]. Approximately 93% of burn
patients show clinical signs of a systemic inflammatory
response syndrome before succumbing to their injuries
[11], and this syndrome can deteriorate and develop
into severe sepsis [12]. After burn injury, there is a dra-
matic increase in proinflammatory cytokines in brain as
early as 3 hours (h) [13,14] and a compromised BBB
leading to a large infiltration of macrophages [9]. Benefi-
cial as well as deleterious effects have been ascribed to
immune cells that infiltrate the nervous system after
neural injury [15-19]. Despite the correlation between
cerebral complications in severe burn victims and mor-
tality, burn-induced neuroinflammation continues to be
an underestimated entity in critically ill burn patients
[10].
Gelsolin was first described as a ~90 kDa cytoplasm
actin-binding protein with capping and severing activ-
ities [20]. Further studies have confirmed a secreted gel-
solin isoform in blood plasma [21]. Recent reports have
documented that it also participates in the regulation of
the systemic immune response. Extracellular gelsolin is
involved in host immune recognition of bacterial wall
molecules during cell division or attack by immune
components, while cytoplasmic gelsolin is necessary for
macrophage motility in culture, and its absence is likely
to impair recruitment of macrophages to a site of crush
injury of sciatic nerve [22]. In fact, overexpression of
gelsolin could alter actin dynamics in Jurkat T cells, cor-
relating with inhibition of activation-dependent signaling
pathways [23]. Moreover, cytoplasmic gelsolin depletion
is observed in diverse states of inflammation that are
associated with tissue injury and actin release, including
hemorrhagic shock [24], early sepsis, trauma, and rheu-
matoid arthritis [25]. In addition, its deficiency has been
found to correlate with septic mortality [26] and prog-
nosis [27], suggesting that gelsolin might play a crucial
protective role in the course of sepsis.
Accordingly, gelsolin replacement might be considered
as a potential therapy for the lethal condition of sepsis
[28]. It could solubilize circulating actin aggregates and
shift expressed cytokines toward an anti-inflammatory
profile [28], resulting in a significant reduction of mor-
tality in endotoxemic mice. Since gelsolin has been
shown to significantly blunt neutrophil recruitment to
lungs [29] and to markedly attenuate vascular perme-
ability in burn injury in rats [30], we hypothesized that,
in severe burn injury of mice, a single dose of gelsolin
might attenuate neuroinflammation, which might ulti-
mately protect the brain from injurious effects following
the acute insult.
Methods
Animal model of burn injury
Male Balb/c mice (20-25 g, 8-9 weeks old, obtained
from the Laboratory Animal Institute, Beijing, China)
were anesthetized, and the dorsal and lateral surfaces of
the mice were shaved. Mice were secured in a protective
template on their backs with an opening corresponding
to 15% of the total body surface area (TBSA), and the
exposed skin was immersed in 95°C water for 8 seconds
(s). This procedure has been shown to produce a 15%
TBSA full-thickness scald injury. Sham-injured mice
were subjected to all of the procedures except that the
temperature of the bath was the same as room tempera-
ture. Immediately following injury, the mice were dried
and allowed to recover under a heating lamp. Both
sham- and burn-injured mice received 1.0 ml of fluid
for resuscitation intraperitoneally (i.p.) (Ringer’ss o l u -
tion). Animals were then housed in individual cages in a
temperature and humidity controlled room with 12
hours (h) light and 12 h darkness before being sacri-
ficed. All experimental manipulations were undertaken
in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals, with
the approval of the Scientific Investigation Board of the
Chinese PLA General Hospital, Beijing, China.
Intravenous gelsolin infusion
Animals were randomly divided into five groups: intact
controls, sham-burn mice, placebo controls that under-
went burn injury with an equivalent amount of bovine
serum albumin (BSA; Fisher Scientific, Fair Lawn, NJ),
and burned mice treated with either a low dose (2 mg/
kg, Gsn-L) or a high dose (20 mg/kg, Gsn-H) of recom-
binant human gelsolin (Sigma-Aldrich, Shanghai,
China), according to a previous report [31], in 0.1 ml of
sterile saline via tail vein immediately after burn injury.
Then the animals (9-10 mice per group) were sacrificed
at 8, 24, 48 and 72 h postburn (pb). Tissue and plasma
samples were collected and stored at -80°C.
Survival rate
Survival rates were recorded for the low- or high-dose
gelsolin-treated mice (n = 30 per group), the placebo-
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10) without further intervention. Differences in survival
r a t e sa m o n gt h eg r o u p sw e r ea n a l y z e db yt h eK a p l a n -
Meier method using an SPSS software package.
Functions of T lymphocytes
Splenic mononuclear cells (MNC) were separated by
Ficoll-Paque density centrifugation and were cultivated
in complete RPMI-1640 medium in flat-bottomed 96-
well microtitre plates (4 × 10
5 cells per well) stimulated
by the T-cell mitogen concanavalin A (ConA, 5 mg/L;
Sigma) for 48 h. Cell-free supernatant fractions were col-
lected and stored at -80°C until analysis for IL-2 by
ELISA (ExCell Biology Inc., Shanghai, China). T cell pro-
liferation was examined using a 3-(4, 5-dimethylthiazol
-2-yl)- 2, 5-diphenyltetrazolium bromide (MTT) method
with absorbance at 450 nm in a multiplate spectrophot-
ometer (Spectra MR; Dynex, Richfield, MN, USA).
Tissue preparation for immunostaining
Mice (3-4 per group) were killed by cervical dislocation
and the brains were removed and post-fixed for 24 h in
4% paraformaldehyde solution, followed by 30% sucrose
in phosphate buffer saline (PBS) for another 24-48 h.
Brains were stored at -80°C until used to prepare frozen
sections at 30 μm thickness. These were serially col-
lected in PBS and finally stored in cryoprotectant solu-
tion at -30°C. Some of the brain sections were mounted
on lysine-coated slides and stained with hematoxylin
and eosin (H&E).
Quantitative polymerase chain reaction (PCR)
Brains from the remaining mice (5-6 mice per group)
were carefully dissected and collected, snap frozen in
liquid nitrogen, and stored at -80°C. Different regions
(cortex, hippocampus and striatum) were used for total
RNA extraction using a NucleoSpin
® RNA II Kit
(Macherey-Nagel Inc., PA, USA) following the manufac-
turer’s instructions, and used for cDNA synthesis with
Superscript II (Promega, Beijing, China). Real-time PCR
amplification was achieved in 25 μl reaction mixtures
containing 5 μl of cDNA sample, 12.5 μl of SYBR Green
PCR Master Mix (SYBR green; Applied Biosystems, Fos-
ter City, CA, USA) and specific primers (SBS Genetech
Co. Ltd, Beijing, China). An ABI Prism 7700 sequence
detection system (Applied Biosystems) with SYBR-green
fluorescence was used for assay. Cycling conditions were
a 10-min hot start at 95°C followed by 5 cycles of dena-
turation steps at 95°C for 40 s, an annealing step at 60°
C for 30 s, and an extension temperature at 72°C for 30
s. Each sample was run in triplicate. b-actin was used as
housekeeping mRNA to normalize gelsolin transcript
abundance. Data were analyzed by using sequence
Detector Systems version 2.0 software.
Each sample was tested in triplicate. The relative con-
centration of mRNA was calculated using the formula x
=2
-ΔΔCt, where x fold change in the target gene at each
detection time, normalized to b-actin and relative to the
expression of intact mice [32].
Immunohistochemistry
Sections used for immunocytochemistry were incubated in
0.3% hydrogen peroxide (H2O2) for 10 min, and incubated
free-floating in antibodies (Abs) of polyclonal anti-mouse
ionized calcium-binding adapter molecule 1 (Iba-1, 1:1000;
Wako, Osaka, Japan), monoclonal anti-mouse CD11b
(Mac-1, 1:1000; EuroBioScience, Lund, Sweden), monoclo-
nal anti-mouse CD45 (1:1000; EuroBioScience), or rabbit
anti-cleaved caspase-3 (1:50; Cell Signaling, Danvers, MA,
USA) with 3% normal goat serum, 0.05%Triton-X in PBS,
for 24-48 h rotating at 4°C. The tissue was then rinsed in
PBS and incubated for 1 h in biotinylated anti-rabbit IgG
(1:200; Vector Laboratories, Burlingame, CA, USA), rotat-
ing at room temperature. The tissue was then rinsed in
PBS and incubated for 1 h in ABC solution (Vector
Laboratories). Following incubation, sections were rinsed
with PBS for 20 min and were developed by incubating in
0.025% diamino-benzidine (DAB; Sigma-Aldrich) and
0.002% H2O2 in PBS. The DAB reaction was halted using
PBS, followed by three 10-min PBS rinses.
Quantification of immunohistochemistry
For quantitative image analysis of periventricular immu-
nostaining, serial sagittal sections of one hemisphere
were collected (lateral position +0.5 to +2.25 from
Bregma). Iba-1-, CD11b- and CD45-immunostained pre-
parations of sagittal brain sections were evaluated for 4-
5 animals from each group. For each animal, antigens
were detected in 10 parallel sections having a distance
of 70 mm from each other and showing both striatum
and cortex. All images were acquired on a BX-61 micro-
scope (Olympus Optical Co., Tokyo, Japan), equipped
with a digital camera (F-View II; Olympus Optical Co.).
Quantification of immunoreactive cells within the cortex
and the striatum was performed at 40 × magnification
by a researcher blinded to the treatment. For each ani-
mal, average values from all sections were determined.
Neuron-specific enolase (NSE) and soluble protein-100
(S100) detection
Brain tissues were weighed and homogenized after addi-
tion of 3 ml/g (1:4) saline with protease inhibitor cock-
tail (Applygen Technologies Inc., Beijing, China). The
supernatants were collected for NSE and S100 analysis
in duplicate using available quantitative ‘sandwich’
enzyme-linked immunosorbent assay kits (Rapidbio, CA,
USA). Sensitivity of the assays was 1.0 pg/ml for S100
and 0.1 ng/ml for NSE.
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The dissected brain tissues were collected, snap-frozen in
liquid nitrogen and stored at -80°C. Tissue was homoge-
nized in RIPA buffer with protease inhibitor (Applygen
Technologies Inc.). The total amount of protein was
determined by bicinchoninic acid protein assay (Apply-
gen Technologies Inc.). Samples (100 μgp r o t e i n )w e r e
separated by 8% SDS-PAGE and electroblotted to nitro-
cellulose membrane, which were blocked by incubation
in 3% (w/v) bovine serum albumin dissolved in TBS-T
(150 mM NaCl, 50 mM Tris, 0.05% Tween 20). Following
transfer, proteins were probed using a rabbit monoclonal
phospho-p44/42 extracellular regulated kinase 1/2
(ERK1/2) (1:2000; Cell Signaling) in TBS-T. Horseradish
peroxidase-conjugated secondary Ab was used at a
1:1000 dilution in TBS-T. After extensive washing, pro-
tein bands detected by Abs were visualized by ECL
reagent (Applygen Technologies Inc.) after exposure on
autoradiograph film (Fuji Film; Kodak Scientific Imaging
Film, Beijing). Membranes were then stripped and re-
probed with p44/42 MAPK (ERK1/2) mouse monoclonal
Ab (1:1000; Cell Signaling) to confirm equal protein load-
ing. The films were subsequently scanned, and band
intensities were quantified using Image software.
Assessment of cysteinyl aspartate-specific protease
(caspase)-3 activity
Caspase-3 activity was measured using a colorimetric
assay according to the manufacturer’s instructions (Bio-
V i s i o n ,M o u n t a i nV i e w ,C A ,U S A ) .T h eb r a i nt i s s u e s
w e r el y s e di nb u f f e r( 5 0m MH E P E S ,p H7 . 4 ,0 . 1 %
CHAPS, 1 mM DTT, 0.1 mM EDTA and 0.1% Triton
X-100) and centrifuged at 12, 000 × g for 10 min at 4°C.
After determination of protein concentration by bicinch-
oninic acid method (Applygen Technologies Inc.), the
cell extract (200 μg of protein) was added to the assay
buffer (100 mM HEPES, pH 7.4, 0.1% CHAPS, 10 mM
DTT, 10% glycerol, and 2% (v/v) dimethylsulfoxide) con-
taining chromogenic substrates (2 mM) and incubated
for 4 h at 37°C. Caspase-3 activity was determined by
measuring the absorbance at 405 nm using a microplate
reader (Spectra MR; Dynex, Richfield, MN, USA).
Determination of plasma gelsolin concentrations
At 8, 24, 48 and 72 h after burns or sham injury, the
animals were anesthetized, and blood obtained by car-
diac puncture was placed in a heparinized tube (n = 6
samples each group per time point). The blood was cen-
trifuged and plasma gelsolin concentrations were deter-
mined in duplicate with a mouse gelsolin ELISA
detection kit (USCN Life, Wuhan, China).
Statistic analysis
All data are expressed as mean ± SD from three or
more independent experiments. Statistical comparisons
among different groups were done by one-way analysis
of variance (ANOVA) with Dunnett’s multiple compari-
son tests using SPSS software (IBM, Beijing, China). Dif-
ferences with p < 0.05 were considered statistically
significant.
Results
Administration of gelsolin can improve the survival rate
of burn mice
The survival of gelsolin-treated mice at low (Gsn-L) or
high doses (Gsn-H), as well as of placebo-treated mice,
was assessed over a 168 h period after burn injury (Fig-
ure 1). All the mice exposed to sham injury survived the
entire period (n = 10). Placebo-treated mice had a
higher mortality than Gsn-H mice (70% versus 43.33%,
p < 0.05) within 72 h after burn injury, and no further
mortality occurred after that observation period. Mean
survival time was prolonged in the Gsn-H group (51.17
± 4.7 h, p = 0.0258 versus placebo) and the Gsn-L
group (43.13 ± 4.46 h, p = 0.4875 versus placebo) in
comparison with the placebo group (35.5 ± 4.96 h).
Nevertheless, there was no significant difference in
mean survival time between Gsn-L and Gsn-H groups
(P = 0.0791).
Treatment with gelsolin obviously ameliorated burn-
induced brain damage
As compared with sham-injured mice (Figure 2A), the
brains of mice subjected to thermal injury exhibited
typical pathological lesions. There was invasion of dis-
persed, or even clustered leukocytes in the cortex
Figure 1 Survival rates in burn-injured mice after treatment
with exogenous gelsolin at low (Gsn-L) or high dose (Gsn-H).
There was greater mortality for placebo (burn, 21 of 30) than for
Gsn-H-treated (13 of 30) mice after thermal injury, and survival time
was significantly shorter in placebo-injected mice than in Gsn-L or
Gsn-H-treated mice.
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pb. Concurrently, neurons were shrunken with con-
densed nuclei, suggesting an early stage of apoptosis
(Figure 2D). As late as 24 h pb, a dispersed infiltration
of leukocytes (Figure 2E) and even microabscesses (Fig-
ure 2F) were seen in the cortex of the mice, indicating a
progressive infiltration of inflammatory cells in brain
over this time period. At 24 h pb, dispersed leukocytes
were still observed in the cortex of Gsn-L mice, suggest-
ing that treatment with gelsolin at low dose fails to ame-
liorate the burn-induced brain injury (Figure 2G). In
contrast, administration of gelsolin at high dose could
protect the brain from undergoing the pathological
changes described above (Figure 2H). Similar results
were also obtained for Gsn-H mice at other time points
(data not shown).
Figure 2 Representative images of H&E-stained sections, highlighting cerebral sparing by high dose gelsolin in burn-injured mice.
Cortex of control mice (A) and burned mice at 8 h postburn (B, C, D), 24 h postburn (E, F) and 24 h following low dose (G) and high dose (H)
gelsolin treatment. Images of the lateral ventricles, including the choroid plexus, at 8 h (I), 24 h (J) postburn, and 24 h after gelsolin treatments
at low dose (K) and high dose (L) respectively. ®: leukocyte, ➤: neurosis, *: microabscess.
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ependymal layer of the lateral ventricle as early as 8 h
pb (Figure 2I). In the worst situation, the lateral ventri-
cle was filled with inflammatory exudates at 24 h pb
(Figure 2J). Moreover, a few leukocytes were observed
to accumulate in the choroid plexus in brain of Gsn-L
mice (Figure 2K), but seldom in Gsn-H mice (Figure
2L) at 24 h pb.
Consistent with the morphological observations, the
neural injury markers cerebral S100 and NSE content
were reduced by high dose gelsolin treatment at 24 h
pb, while these remained at levels similar to control or
sham-burned mice at 8 h pb (Figure 3). It is noteworthy
that both S100 and NSE showed a small trend of
increase at 48 h pb, which could also be slightly reduced
by gelsolin infusion at high dose.
Figure 3 Gelsolin at high dose (Gsn-H) reduces brain-specific proteins, S100 (A) and NSE (B), in mice following burn injury. All data are
expressed as mean ± SD of the mean (n = 6). *P < 0.05 vs. intact control, #p < 0.05 vs. sham-injured, +p < 0.05 vs. placebo mice.
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proinflammatory cytokines in the brain
To further validate and explore the above findings, we
n e x ti n v e s t i g a t e dt h et i m ec o u r s eo fm R N Ae x p r e s s i o n
of proinflammatory cytokines by real-time PCR in brain
of burned mice. On account of the lack of significant
improvement in pathology in Gsn-L mice, only the gene
expression of proinflammatory cytokines in the brains of
Gsn-H mice was determined.
Significant reductions in brain levels of early cyto-
kines, including IL-1b and IL-6 mRNA expression, and
late cytokine high mobility group box-1 protein
(HMGB1), were found in the gelsolin-treated group
compared to the placebo group at all time points (Figure
4). Most strikingly, IL-1b mRNA expression in the pla-
cebo mice spiked rapidly, and continued to increase at
various time points (Figure 4A). IL-6 mRNA expression
in brain tissue was increased by approximately 1.5- to 2-
fold that of the placebo group compared to normal con-
trols following thermal injury (Figure 4B). Gelsolin
injection resulted in marked down-regulation of IL-1b
mRNA expression compared with the placebo group.
Similarly, IL-6 mRNA levels in the brain were sup-
pressed by approximately 70% in the gelsolin-treated
group compared with the placebo group, close to that of
the sham-injured group (Figure 4B).
HMGB1 is a non-histone DNA binding protein that is
secreted by activated monocytes and macrophages [33],
and passively released by necrotic or damaged tissues
[33-35] including brain [36]. Thus, HMGB1 acts as an
immediate trigger of inflammation [37] as well as a late
mediator of inflammation [33]. We found that HMGB1
levels were significantly elevated in the brain at 24 and
48 h pb, while they were markedly decreased by gelsolin
treatment at both dosages (Figure 4C).
In addition, we did not find changes in IL-17A or IL-
10 mRNA in the brain tissue, implying that there might
be no T cell infiltration in brain secondary to acute
burns. Similarly, there was no expression of anti-inflam-
matory cytokines, including IL-10 mRNA, induced by
gelsolin infusion (data not shown).
Administration of gelsolin suppressed burn-induced
microglial activation in the brain
Microgliosis is a common feature of central nervous sys-
tem (CNS) injury and disease, and this involves micro-
glial cell division, hypertrophy, and alterations in
immunophenotype as well as secretory activity [38]. The
augmented neuroinflammation may lead to dysregula-
tion of microglial number and/or microglial activation
i nt h eC N S .T ot e s ts u c hah y p o t h e s i s ,w es t a i n e d
microglial populations in brains of burned mice with the
microglial marker (Iba-1) at different intervals.
We observed kinetic changes of Iba-1-immunoreactive
cells in striatum and cortex after thermal injury. In
brief, Iba-1-immunoreactive cells showed morphological
changes and altered immunoreactivity in cortex, stria-
tum and CA1 region with time after acute insults, peak-
ing at 72 h pb in the striatum region (Figure 5A). Iba-1
+
cells were well ramified in burned mice in contrast with
a highly ramified ‘resting’ morphology in sham-injured
brain (Figure 5B). These alterations might be associated
with delayed neuronal death of striatum cells in burned
mice. In contrast, gelsolin administration at either
dosage could suppress activation of Iba-1
+ microglia in
cortex and striatum as exemplified by mice at 72 h pb,
correlating with its anti-inflammatory effect in brain
(Figure 5C).
Taken together, immunohistochemistry analyses
revealed enhanced microglial density and activation sta-
tus in brain at 72 h pb, implicating delayed activation of
microglial proliferation and/or activation responses after
thermal injury.
Caspase-3 activation in the brain was inhibited by
gelsolin infusion after burn injury
Caspase-3-positive cells were detected in striatum of
burned mice by immunofluorescence (Figure 6A).
Immunohistochemistry analysis also verified reduced
caspase-3-positive cells in both cortex and hippocampus
by gelsolin treatment (Figure 6B). To determine if gelso-
lin could inhibit caspase-3 activation in our model, we
measured levels of caspase-3 activity in the brain tissue.
We found that there was an approximately 2-fold
increase in caspase-3 activity in the placebo group in
comparison to the sham group at 24 h and 48 h pb.
However, at early 8 h and later 72 h time points, there
were no marked differences in caspase-3 activity
between the placebo and sham groups. As expected, gel-
solin injection either at low or high dosage could reduce
the elevated caspase-3 activity to levels comparable to
sham-injured mice at 24 h pb, while at later time points
such as 48 h pb, only the high dose of gelsolin could
exert a similar effect (Figure 6C).
Gelsolin enhanced CD11b and CD45 monocyte/
macrophage recruitment into brain following burn injury
CD11b is expressed by mature monocytes [16] and by
monocyte-derived microglia-like cells [39], and CD45 is
a pan-leukocyte marker. Unexpectedly, an increase in
absolute numbers of macrophage/microglial cells
(CD11b
+CD45
+) [40] was found in the gelsolin-treated
groups. It is intriguing that numerous CD11b
+ infiltrat-
ing monocytes and resident microglial cells with promi-
nent amoeboid morphology were noted in the
periventricular regions at 24 h pb (Figure 7A). This
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Page 7 of 18Figure 4 Gelsolin administration protects against burn-induced proinflammatory cytokine expression in brain. Elevated levels of IL-1b
(A) and IL-6 (B) mRNA, as well as HMGB1 content (C) were found in cortex after burn injury. Data are shown as mean ± SD for n = 6. *P < 0.05
and **P < 0.01 vs. sham-injured mice; #p < 0.05, ##p < 0.01, ### p < 0.001 vs. placebo mice; +p < 0.05 and ++p < 0.01 vs. Gsn-L by ANOVA,
Newman-Keuls post-hoc test.
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glia or macrophages. Since gelsolin is known as a strong
chemoattractant [22], we further investigated the invol-
vement of gelsolin in the migration of myeloid-origin
cells into the brain. To our surprise, the numbers of
CD11b
+ cells were increased in sham and burn-injured
groups as late as 72 h pb, implying that activation of
CD11b
+ cells was delayed. By contrast, the number of
CD11b
+ cells was decreased by treatment with gelsolin
at both dosages (Figure 7B). However, CD45
+ macro-
phages accumulated in the perivascular regions at 8 h
pb in the Gsn-H group (Figure 8A). At both 8 h and 24
h pb, numbers of CD45
+ cells were arrested in the peri-
ventricular region by both doses of gelsolin administra-
tion with differential effects (Figure 8B).
Gelsolin down-regulated burn-mediated ERK1/2
phosphorylation in brain
Western immunoblotting for the active, dually phos-
phorylated form of p44/42 mitogen-activated protein
kinase (MAPK) (ERK1/2) revealed that thermal injury
per se resulted in activation of this signal pathway in
b r a i nt i s s u e( F i g u r e9 ) .A ni n c r e a s ei np h o s p h o r y l a t i o n
o fp 4 4 / 4 2M A P Kw a so b s e r v e da t8hp b ,a n dt h i sw a s
remarkably increased at 24 h pb. ERK1 (44 kDa) density
of the sham group was 18, 207 ± 829, while it reached
25, 564 ± 914 and 30, 546 ± 1077 in burned mice at 8 h
and 24 h, respectively (P < 0.05). Exogenous infusion of
gelsolin could markedly down-regulate ERK1/2 phos-
phorylation at 24 h pb (12, 883 ± 877).
Gelsolin improved the suppressed T lymphocytes
functions induced by burn injury
As expected, burn injury resulted in dramatic suppres-
sion of T cell function, as shown by decreased prolifera-
tion (Figure 10A) and IL-2 secretion (Figure 10B),
compared with either intact control or sham-burned
mice. Although infusion of gelsolin at high dose could
partially prevent the decline, gelsolin at low dose failed
to exert any effect on T cell function.
Figure 5 Treatment with gelsolin reduces microglial activation, as assessed by ionized calcium binding adaptor molecule 1 (Iba-1)
expression after burn-induced neuroinflammatory responses in the cortex 24 h postburn shown at low (A, × 200) and high (B, × 400)
magnifications. Cell counting in cortex and striatum was performed to show that the increased Iba-1 levels after thermal injury were
suppressed by a high dose of gelsolin 72 h postburn (C). All pictures are representative of brain sections from 3 mice for each time point. *P <
0.05 and **P < 0.01 vs. sham-injured mice; ##p < 0.01 vs. placebo mice; ++p < 0.01 vs. Gsn-L mice by ANOVA, Newman-Keuls post-hoc test.
Data are means ± SD for n = 6.
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Page 9 of 18Figure 6 Gelsolin decreases caspase-3 activities in brain of mice following burn injury. A. Immunofluorescent staining of caspase-3 in
striatum of brain 24 h postburn; B. Immunohistochemistry of caspase-3 positive cells in the cortex and hippocampus (hippo) from mice under
gelsolin treatments. C. Time course of caspase-3 activity in brain as assayed by colorimetry. *P < 0.05 and **P < 0.01 vs. sham-injured mice; #p <
0.05 and ##p < 0.01 vs. placebo mice by ANOVA, Newman-Keuls post-hoc test. Data are means ± SD for n = 6-8.
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Page 10 of 18Figure 7 Gelsolin affects migration of myeloid-derived cells into brain. CD11b+ cells from mice 72 h postburn (A) and quantification of
infiltrating CD11b+ (B) cells in 10 high power fields (HPF) of the periventricle region following gelsolin treatment. Gelsolin positive cells were
seen in medial habenular nucleus (MHb, a), hippocampal CA field (CA2, b), corpus callosum (cc, c), bed nucleus striatum terminal (BST, d),
choroid plexus (e), cortex (f), lateral ventricle (g, h) and amplified lateral ventricle (g’,h ’). Magnifications for “a-f” and “g’-h’” are × 400, “g-h” are ×
200. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. sham-injured mice; #p < 0.05, ## p < 0.01, ### p < 0.001 vs. placebo mice; ++p < 0.01, and +++p
< 0.001 vs. Gsn-L mice by ANOVA, Newman-Keuls post-hoc test. Data are means ± SD for n = 6-8.
Zhang et al. Journal of Neuroinflammation 2011, 8:118
http://www.jneuroinflammation.com/content/8/1/118
Page 11 of 18Figure 8 Gelsolin affects migration of myeloid-derived cells into brain.C D 4 5
+ cells from gelsolin-treated mice 8 h postburn (A) and
quantification of infiltrating CD45
+ (B) cells in 10 high power fields (HPF) of the periventricle region following gelsolin treatment. Gelsolin
positive cells were seen in medial habenular nucleus (MHb), stria medullaris (sm), hippocampal CA field (CA2) and blood vessel (BV).
Magnifications are × 400. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. sham-injured mice; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. placebo mice; +
+p < 0.01, and +++p < 0.001 vs. Gsn-L mice by ANOVA, Newman-Keuls post-hoc test. Data are means ± SD for n = 6-8.
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Page 12 of 18Kinetic changes in plasma gelsolin concentrations
To evaluate kinetic changes in circulating gelsolin in
various groups in the study, we measured plasma gelso-
lin concentrations to determine its bioavailability. We
found that in animals receiving gelsolin, there were not
dramatic changes in circulating gelsolin concentrations.
As exemplified in the Gsn-H group, gelsolin concentra-
tions ranged from 851 ± 32 pg/ml at 8 h pb to 844 ±
128 pg/ml at 72 h pb. Baseline values of plasma gelsolin
in both the intact control and placebo groups was
approximately 1300 pg/ml, and they remained relatively
constant at all observed time points (Table 1). Following
burn injury, plasma gelsolin levels dropped rapidly to
only 1/3 of the sham group within 8 h (407 ± 57 versus
1273 ± 145, P < 0.001) and remained at low levels for
up to 3 days. Although plasma gelsolin levels in the
Gsn-H group were almost twice that of the placebo
group at most time points, gelsolin administration in
both dosages could only prevent part of the reduction in
plasma gelsolin levels that accompanied burn injury
compared with the sham-burned group.
Discussion
A successful therapeutic strategy for brain injury should
include inhibition of proinflammatory cytokines, promo-
tion of anti-inflammatory cytokines, suppression of
autoimmunity to CNS antigens and reduction in recruit-
ment of inflammatory cells, etc. In the present study, we
report protective effects of gelsolin in brain of mice sub-
jected to burn injury, characterized by amelioration of
pathological lesions and suppression of microglial activa-
tion, which might be associated with enhanced recruit-
ment of CD11b
+ as well as CD45
+ cells. Likewise,
gelsolin could substantially down-regulate the marked
expression of both early (IL-1b, IL-6) and late proin-
flammatory cytokines (HMGB1) in the brain. In addi-
tion, treatment with gelsolin significantly reduced
caspase-3 activity and inhibited ERK phosphorylation in
the brain secondary to severe burns.
As a 90 kDa protein, it is not likely that gelsolin easily
penetrates into brain to perform its effects. Yet a pio-
neer study has demonstrated that peripherally expressed
plasma gelsolin can affect amyloid-b dynamics in the
CNS in two mouse models of Alzheimer’s disease (AD)
[41]. The authors suggested that one possible clearance
mechanism might be via plasma gelsolin entrance into
brain parenchyma across the BBB, as reports have indi-
cated that the BBB is compromised in mouse models of
AD [42]. Similarly, an increase in the permeability of the
BBB is a common event in thermally injured animals
[8], as also shown in our study by the filling of the lat-
eral ventricles with inflammatory exudates, so it is rea-
sonable to speculate that intravenous infusion of
gelsolin could penetrate the BBB into brain parenchyma
to attenuate neuroinflammation.
Inflammatory mediators are able to alter cellular
metabolism by inducing oxidative stress and mitochon-
drial dysfunction [43], resulting in pathologic abnormal-
ities [44]. Abnormally high levels of cytokines in brain
have been found to correlate with both morbidity and
mortality in patients with extensive burn injury. In our
study, cerebral IL-1b and IL-6 mRNA were up-regulated
around 8 h pb and kept increasing throughout the entire
period. It is likely that HMGB1 levels were significantly
elevated in brain at both 24 and 48 h pb. Gelsolin treat-
ment could significantly reduce expression and release
of early as well as late proinflammatory cytokines. This
down-regulation of the inflammatory response would
lead to less damage and cell loss in the brain, which
might, in the future, allow preservation of cognition in
patients with severe burn injury. IL-10 is an immuno-
suppressant that is mainly secreted by regulatory T cells.
It is well known for its positive effects in cerebral ische-
mia in rats [45]. We did not detect IL-10 gene expres-
sion in brain during the entire observation period,
suggesting that administration of gelsolin only inhibits
proinflammatory cytokine transcription, without aug-
menting expression of anti-inflammatory cytokines.
Microglial cells are the primary immune effector cells
in brain and play a pivotal role in neuroinflammatory
processes associated with a variety of neurological as
well as pathological disorders. Microgliosis is a common
feature of CNS injury and disease [38]. Iba-1 is specifi-
cally expressed in microglia and plays an important role
in regulation of microglial function. Increased Iba-1
immunoreactivity is a hallmark of burn-induced inflam-
mation. It has been proposed that microglial activation
induced by sepsis is involved in the pathogenesis of
delirium [46]. There are no reports to date dealing with
direct investigation of the activation of microglia and
glial scarring following severe burns. We observed
kinetic changes in Iba-1
+ cells in striatum and cortex
after thermal injury, indicating a highest level of
Figure 9 Gelsolin down-regulates burn-induced phospho-ERK1/
2 activity in hippocampus. Lane 1: sham control, Lane 2: 8 h
postburn, Lane 3: 24 h postburn, Lanes 4-5: Gsn-H 24 h postburn.
The ERK1/2 blotting displayed equal loading between wells.
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Page 13 of 18Figure 10 Gelsolin restores suppressed T lymphocyte function after burn injury. Splenic mononuclear cells harvested from the mice under
different treatments were cultured in the presence of the T-cell mitogen concanavalin A (5 mg/L) for 48 h. T-cell viability was determined by
MTT methods (A) and the supernatants were collected for IL-2 analysis (B). Data are shown as mean ± SD for n = 6-8. *P < 0.05 vs. intact
control; #p < 0.05 vs. sham-injured mice; &p < 0.05 vs. placebo mice by ANOVA, Newman-Keuls post-hoc test.
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Page 14 of 18activation as late as 72 h pb. A number of studies have
demonstrated that activated glial cells participate in the
degeneration of dopamine neurons [47]. Our data sug-
gest that burn injury per se might result in microgliosis
and loss of vulnerable neuronal populations from
inflammation-induced cell death.
Inflammation and apoptosis are two of the most
important underlying causes of septic encephalopathy
[48]. Because local accumulation of cytokines may
induce apoptosis and significantly extend the initial
injury, we also wanted to clarify whether the ability of
gelsolin to down-regulate cytokine signaling could lead
to decreased activation of apoptotic proteins in brain.
Previous investigations have documented that severe
burn injury is associated with a significant increase in
apoptosis in remote organs [30,49,50] including brain
[47]. A number of markers such as S100B and NSE can
serve as general markers of brain injury. Consistent with
our observation of morphological improvement, cerebral
S100B and NSE levels were diminished by gelsolin infu-
sion. Our study further proves that gelsolin administra-
tion immediately following burn injury can reduce
caspase-3 activity in brain, confirming a neuroprotective
effect of gelsolin.
In inflammatory diseases either inside or outside the
CNS, communication between the periphery and the
brain via humoral and/or neural routes results in central
neural changes and related behavioral alterations.
Monocytes are circulating antigen-presenting leukocytes
that play critical roles in inflammation, T-cell differen-
tiation, phagocytosis, and innate immunity [51,52]. Pre-
vious studies have reported significant infiltration of
activated monocytes into the brain of mice with hepatic
inflammation [18], stroke [19], ischemia-reperfusion [15]
and bacterial meningitis during the post-inflammatory
period [16]. Importantly, these newly recruited mono-
cytes became an integral part of the pool of parenchyma
microglia and contribute to the clearance of damaged
tissue [17]. CD11b is expressed by mature monocytes
[16] and monocyte-derived microglia-like cells [39],
whereas CD45 is a pan-leukocyte marker. Resolution of
CNS infection is often the result of a balance between
immune-mediated pathogen clearance and the
deleterious effects of inflammation. Indeed, in a murine
model of rabies encephalitis, administration of a sex
steroid enhanced permeability of the BBB, promoted
immune cell penetration into the CNS, and improved
survival [53]. It has also been reported that gelsolin is
necessary for rapid motile responses in cell types
involved in stress responses such as hemostasis, inflam-
mation and wound healing [54]. In gelsolin-mutant
mice, macrophage motility was impaired and this contri-
butes to a reduced inflammatory response [54] and a
reduced capacity to recruit macrophages to the injury
site, which in turn, slows the clearance of myelin debris
and consequently remyelination [22]. Consistent with
these findings, we noticed that gelsolin infusion could
accelerate the recruitment of CD11b
+ and CD45
+ cells
into the periventricular region of brain early after burn
injury, but could still exert a suppressive effect on their
recruitment at 72 h pb, indicating an early recruitment
of monocyte/macrophage by gelsolin. The increased
penetration of CD11b+ cells and the enhanced micro-
glial activation in gelsolin-treated animals were found to
be associated with down-regulation of proinflammatory
cytokines and caspase-3 activities. Taken together, these
results indicate that treatment with gelsolin could ame-
liorate inflammatory responses in brain and apoptosis of
cerebral cells after burn injury.
To elucidate the potential signaling mechanism under-
lying gelsolin-mediated neuroprotective activity, we
examined expression levels of phospho-ERK in burn
mice. Western blotting experiments using anti-phospho-
p44/42 MAPK (ERK1/2) mouse antibodies revealed acti-
vation of phospho-ERK in brain following thermal
injury, which is consistent with previous reports [7,13].
ERK activation may be downstream of free radicals for-
mation, based on the finding that dopaminergic cells
exposed to 6-hydroxydopamine, a reactive oxygen spe-
cies generating neurotoxin, exhibit a distinct temporal
pattern of ERK1/2 activation and caspase-3 activity [55].
It has been demonstrated that neurons are damaged fol-
lowing prolonged exposure to high concentrations of
corticosterone, with activation of p38 MAPK, ERK1/2,
and c-jun N-terminal protein kinase 1 [56], particularly
in chronic inflammatory and immune diseases. The
Table 1 Circulating levels of gelsolin (pg/ml) after exogenous gelsolin administration in mice after burn injury.
group 0 h 8 h 24 h 48 h 72 h
control 1294 ± 113 1295 ± 81 1276 ± 77 1297 ± 69 1229 ± 50
sham 1295 ± 111 1273 ± 145 1284 ± 96 1290 ± 135 1292 ± 68
burn+placebo 1136 ± 52 407 ± 57* 484 ± 117* 559 ± 106* 529 ± 169*
burn+Gsn-L 1216 ± 52 662 ± 67*
# 862 ± 67*
# 803 ± 197*
# 817 ± 125*
#
burn+Gsn-H 1193 ± 104 851 ± 32*
#+ 923 ± 63*
# 956 ± 87*
#+ 844 ± 128*
#
*P < 0.05 vs. the sham-injured group; #p < 0.05 vs. the placebo group; +p < 0.05 vs. the Gsn-L group by ANOVA, Newman-Keuls post-hoc test. Data are means ±
SD for n = 6-8.
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Page 15 of 18increased phospho-ERK levels in brain following burn
injury might be a consequence of multiple factors,
including proinflammatory mediators, ischemia, and oxi-
dative stress.
We further found that gelsolin treatment dramatically
inhibits expression of phospho-ERK1/2 in brain of
burned mice. These biochemical results are not in
agreement with a previous observation that the neuro-
protective effects of estrogen could be attributed to
increased phospho-ERK in brain [13]. However, other
authors have reported that administration of neuropro-
tective reagents reduces phospho-ERK1/2 activity
[57,58], and inhibition of ERK1/2 can protect against
brain damage resulting from focal cerebral ischemia
[59]. Furthermore, it has been demonstrated that gelso-
lin overexpression inhibits ERK1/2 phosphorylation,
nuclear factor of activated T-cell activation, and IL-2
production [23]. Thus, the exogenous supply of gelsolin
in our experiments might protect the brain from expo-
sure to pro-apoptotic stimuli, which in turn might
down-regulate ERK1/2 phosphorylation.
Although cerebral complications have been related to
increased mortality in severe sepsis [60] and major burn
victims [10], attenuation of neuroinflammation might
not account for all of the benefit of gelsolin in reducing
burn-induced mortality in our study. Considering that
burn injury could result in severe suppression of the
immune system, which plays an important role in the
development of subsequent sepsis, multiple organ failure
and even death, we examined the dynamic changes in
immune function of splenic T cells as well. We found
an immunosuppressive effect involving T cells following
burn injury, which is consistent with a previous report
of perturbed T cell homeostasis after burn injury [61]. It
was encouraging to find that gelsolin infusion could
markedly enhance cell-mediated immunity of splenic T
cells, which might also contribute to reduced post-burn
mortality.
W h i l et h e s es t u d i e sa r ei n t r i g u i n g ,t h e r ea r es e v e r a l
limitations that should be addressed in future investiga-
tions. The first shortcoming is that clinical outcome
variables were not obtained. For clinical relevance,
multi-organ dysfunction which may be the root cause of
burn-induced mortality should be evaluated in further
studies. Secondly, neurological outcomes like edema,
BBB penetrability and cognitive function were not
assessed in the current study. Better understanding of
the improvement of neurological outcome with gelsolin
may allow an in-depth understanding of the mechan-
isms by which gelsolin attenuates the acute response,
and to what extent neurological damage contributes to
post-burn mortality. Although we initiated this study to
observe the acute effects of gelsolin on neuroinflamma-
tion following burn injury, it may be possible to solidify
our current observations in a further study by also eval-
uating the effects of gelsolin on these neurological com-
plications which are frequently seen in our clinical
patients. Thirdly, with regard to the time-window of gel-
solin delivery, intravenous infusion of gelsolin immedi-
ately after burn injury resulted in significantly reduced
mortality. However, the interventional time could be
postponed to later intervals to more closely simulate a
clinical setting for this therapeutic strategy. The final,
but foremost concern regards the pharmacokinetics of
gelsolin in this model. With a half life as long as 2.3
days [62], a single administration of gelsolin could pro-
duce considerably elevated gelsolin levels as early as 8 h
and remained high at 72 h pb. As BBB disruption may
occur as early as 7 h after burn injury [8], while gelsolin
might not penetrate the BBB directly within the first
hours, and it is reasonable to speculate that gelsolin
could breach the BBB to perform its effect directly in
the brain at later time points. Nevertheless, the precise
mechanism of our observed gelsolin effect on response
to thermal injury and immunomodulation in both the
brain and the periphery requires further studies.
Conclusion
Despite these limitations, we conclude that, following
severe burn injury in a rodent model, an early, single
dose of gelsolin can dramatically reduce mortality by
ameliorating cerebral inflammatory lesions and apopto-
sis via acceleration of recruitment of monocytes and
down-regulation of phospho-ERK1/2 expression, and
also via improvement of peripheral T cell functions as
well. Although further studies are warranted, these find-
ings might be of importance in the near future in the
development of a safe and effective new therapy aimed
at significantly improving the outcome of patients with
severe burns.
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